ValiRx plc (AIM: VAL), a specialist in early-stage cancer therapeutics and women's health, reported on Monday that it has extended a commercial agreement between its wholly owned subsidiary Inaphaea BioLabs and Dominion Biotech Ltd.

Under the extension, Inaphaea will share access to results from its proprietary 3k Screen of approximately 3,000 FDA-approved drugs, originally authorised for non-cancer uses, using patient-derived cells. Dominion will analyse the data for potential oncology applications, validate top candidates independently, and jointly conduct further studies if needed.

Both parties will co-own the resulting data and share equally in costs associated with patent filings. Revenues from any repurposed drug assets will also be shared equally, net of direct costs. Commercialisation efforts may target original drug developers or new partners interested in repurposed applications.

ValiRx continues to leverage its integrated platform to accelerate the development of innovative therapeutics from preclinical to investor-ready stages.